NEW YORK (GenomeWeb News) – GE Healthcare's Clarient will commercialize Biocept's blood test for circulating tumor cells under a deal announced today.
Clarient will market and sell the OncoCEE-BR test to community hospitals, pathologists, and medical oncologists. Biocept will run the test in its CLIA laboratory and Clarient Pathology Services will analyze the results.
Financial and other terms of the deal were not disclosed.